Dec 11 (Reuters) - Australia's CSL Ltd CSL.AX said on Friday it would not take its COVID-19 vaccine candidate, being developed with the University of Queensland, to phase 2 and 3 clinical trials after trial participants returned false positive HIV test results.
The biotech giant said it came to the decision with the Australian government to not proceed further.